Show simple item record

dc.contributor.authorde Mol van Otterloo, SR
dc.contributor.authorChristodouleas, JP
dc.contributor.authorBlezer, ELA
dc.contributor.authorAkhiat, H
dc.contributor.authorBrown, K
dc.contributor.authorChoudhury, A
dc.contributor.authorEggert, D
dc.contributor.authorErickson, BA
dc.contributor.authorDaamen, LA
dc.contributor.authorFaivre-Finn, C
dc.contributor.authorFuller, CD
dc.contributor.authorGoldwein, J
dc.contributor.authorHafeez, S
dc.contributor.authorHall, E
dc.contributor.authorHarrington, KJ
dc.contributor.authorvan der Heide, UA
dc.contributor.authorHuddart, RA
dc.contributor.authorIntven, MPW
dc.contributor.authorKirby, AM
dc.contributor.authorLalondrelle, S
dc.contributor.authorMcCann, C
dc.contributor.authorMinsky, BD
dc.contributor.authorMook, S
dc.contributor.authorNowee, ME
dc.contributor.authorOelfke, U
dc.contributor.authorOrrling, K
dc.contributor.authorPhilippens, MEP
dc.contributor.authorSahgal, A
dc.contributor.authorSchultz, CJ
dc.contributor.authorTersteeg, RJHA
dc.contributor.authorTijssen, RHN
dc.contributor.authorTree, AC
dc.contributor.authorvan Triest, B
dc.contributor.authorTseng, C-L
dc.contributor.authorHall, WA
dc.contributor.authorVerkooijen, HM
dc.contributor.authorMR-Linac Consortium,
dc.coverage.spatialUnited States
dc.date.accessioned2022-11-28T10:56:19Z
dc.date.available2022-11-28T10:56:19Z
dc.date.issued2021-11-15
dc.identifierS0360-3016(21)00872-5
dc.identifier.citationInternational Journal of Radiation: Oncology - Biology - Physics, 2021, 111 (4), pp. 867 - 875
dc.identifier.issn0360-3016
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5577
dc.identifier.eissn1879-355X
dc.identifier.eissn1879-355X
dc.identifier.doi10.1016/j.ijrobp.2021.07.003
dc.description.abstractPURPOSE: High-field magnetic resonance-linear accelerators (MR-Linacs), linear accelerators combined with a diagnostic magnetic resonance imaging (MRI) scanner and online adaptive workflow, potentially give rise to novel online anatomic and response adaptive radiation therapy paradigms. The first high-field (1.5T) MR-Linac received regulatory approval in late 2018, and little is known about clinical use, patient tolerability of daily high-field MRI, and toxicity of treatments. Herein we report the initial experience within the MOMENTUM Study (NCT04075305), a prospective international registry of the MR-Linac Consortium. METHODS AND MATERIALS: Patients were included between February 2019 and October 2020 at 7 institutions in 4 countries. We used descriptive statistics to describe the patterns of care, tolerability (the percentage of patients discontinuing their course early), and safety (grade 3-5 Common Terminology Criteria for Adverse Events v.5 acute toxicity within 3 months after the end of treatment). RESULTS: A total 943 patients participated in the MOMENTUM Study, 702 of whom had complete baseline data at the time of this analysis. Patients were primarily male (79%) with a median age of 68 years (range, 22-93) and were treated for 39 different indications. The most frequent indications were prostate (40%), oligometastatic lymph node (17%), brain (12%), and rectal (10%) cancers. The median number of fractions was 5 (range, 1-35). Six patients discontinued MR-Linac treatments, but none due to an inability to tolerate repeated high-field MRI. Of the 415 patients with complete data on acute toxicity at 3-month follow-up, 18 (4%) patients experienced grade 3 acute toxicity related to radiation. No grade 4 or 5 acute toxicity related to radiation was observed. CONCLUSIONS: In the first 21 months of our study, patterns of care were diverse with respect to clinical utilization, body sites, and radiation prescriptions. No patient discontinued treatment due to inability to tolerate daily high-field MRI scans, and the acute radiation toxicity experience was encouraging.
dc.formatPrint-Electronic
dc.format.extent867 - 875
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.relation.ispartofInternational Journal of Radiation: Oncology - Biology - Physics
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectHumans
dc.subjectMagnetic Resonance Imaging
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectParticle Accelerators
dc.subjectProspective Studies
dc.subjectRadiotherapy Planning, Computer-Assisted
dc.subjectRegistries
dc.subjectYoung Adult
dc.titlePatterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry.
dc.typeJournal Article
dcterms.dateAccepted2021-07-02
dc.date.updated2022-11-24T14:43:29Z
rioxxterms.versionAM
rioxxterms.versionofrecord10.1016/j.ijrobp.2021.07.003
rioxxterms.licenseref.startdate2021-11-15
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/34265394
pubs.issue4
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Gynaecological Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radiotherapy Physics Modelling
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy/Breast Cancer Radiotherapy (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Gynaecological Cancer/Gynaecological Cancer (hon.)
pubs.organisational-group/ICR/ImmNet
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1016/j.ijrobp.2021.07.003
pubs.volume111
icr.researchteamClinic Acad RT Huddart
icr.researchteamClin Trials & Stats Unit
icr.researchteamTargeted Therapy
icr.researchteamRadiother Phys Modelling
dc.contributor.icrauthorHafeez, Shaista
dc.contributor.icrauthorHall, Emma
dc.contributor.icrauthorHarrington, Kevin
dc.contributor.icrauthorHuddart, Robert
icr.provenanceDeposited by Mrs Jessica Perry (impersonating Prof Emma Hall) on 2022-11-24. Deposit type is initial. No. of files: 1. Files: Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High Field MRLinac Within the MOMENTUM Study; Initial Results From a Prospective Multi Institutional Registry.pdf
icr.provenanceDeposited by Mr Arek Surman (impersonating Prof Emma Hall) on 2022-11-28. Deposit type is subsequent. No. of files: 1. Files: 2019.12.9 Mol van-Otterloo et al.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record